头颈癌长期生存:部位、分期、吸烟与人乳头瘤病毒状态的影响
该前瞻性队列研究纳入卡罗来纳头颈癌研究中诊断后存活5年的581例头颈鳞状细胞癌(HNSCC)病例,比较其10年总生存(OS)与年龄匹配非癌对照的差异。p16阳性口咽癌10年OS为87%,高于口腔(69%)、喉(67%)、p16阴性口咽(56%)及下咽(51%)。即使按p16和吸烟状态分层,HNSCC病例5年后OS仍持续低于对照。
要点
- p16阳性口咽癌10年OS为87%,预后最优。
- p16阴性口咽癌10年OS为56%,下咽癌为51%。
- 按p16和吸烟分层后,病例5年后OS仍低于对照。
核心结论
- HNSCC病例治疗后5年OS继续下降,即使按p16和吸烟状态分层亦如此。
- 部位、分期、吸烟和p16状态是显著因素,为HNSCC提供重要预后信息。
研究设计与样本
- 前瞻性队列研究,病例来自卡罗来纳头颈癌研究,为诊断后存活5年的581例HNSCC患者,与年龄匹配非癌对照比较,并按p16和吸烟状态分层。
主要发现
- 581例中10年OS因部位而异:p16阳性口咽癌87%,口腔癌69%,喉癌67%,p16阴性口咽癌56%,下咽癌51%。
- 与吸烟状态匹配的对照相比,p16阳性口咽癌吸烟者死亡HR为1.5(95%CI 0.7-3.1),非吸烟者为2.4(95%CI 0.7-8.8)。
- 非HPV相关HNSCC吸烟者死亡HR为2.2(95%CI 1.7-3.0),非吸烟者为2.4(95%CI 1.4-4.9)。
- 初始分期影响OS,治疗未影响OS。
关键数值与推荐
- 10年OS:p16阳性口咽癌87%,口腔癌69%,喉癌67%,p16阴性口咽癌56%,下咽癌51%。
- p16阳性口咽癌吸烟者死亡HR 1.5(95%CI 0.7-3.1),非吸烟者HR 2.4(95%CI 0.7-8.8)。
- 非HPV相关HNSCC吸烟者死亡HR 2.2(95%CI 1.7-3.0),非吸烟者HR 2.4(95%CI 1.4-4.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Literature examining long-term survival in head and neck squamous cell carcinoma (HNSCC) with human papillomavirus (HPV) status is lacking. We compare 10-year overall survival (OS) rates for cases to population-based controls. STUDY DESIGN: Prospective cohort study. METHODS: Cases surviving 5 years postdiagnosis were identified from the Carolina Head and Neck Cancer Study. We examined 10-year survival by site, stage, p16, and treatment using Kaplan-Meier and Cox proportional hazard models. Cases were compared to age-matched, noncancer controls with stratification by p16 and smoking status. RESULTS: Ten-year OS for HNSCC is less than controls. In 581 cases, OS differed between sites with p16+ oropharynx having the most favorable prognosis (87%), followed by oral cavity (69%), larynx (67%), p16- oropharynx (56%), and hypopharynx (51%). Initial stage, but not treatment, also impacted OS. When compared to controls matched on smoking status, the hazard ratio (HR) for death in p16+ oropharynx cases was 1.5 (95% confidence interval [CI]: 0.7-3.1) for smokers and 2.4 (95% CI: 0.7-8.8) for nonsmokers. Similarly, HR for death in non-HPV-associated HNSCC was 2.2 (95% CI: 1.7-3.0) for smokers and 2.4 (95% CI: 1.4-4.9) for nonsmokers. CONCLUSIONS: OS for HNSCC cases continues to decrease 5 years posttreatment, even after stratification by p16 and smoking status. Site, stage, smoking, and p16 status are significant factors. These data provide important prognostic information for HNSCC. LEVEL OF EVIDENCE: 2 Laryngoscope, 129:2506-2513, 2019.
引用
- Du E, Mazul AL, Farquhar D, et al. Long-term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status. Laryngoscope. 2019. PMID: 30637762. doi:10.1002/lary.27807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。